

## Tepezza® (teprotumumab-trbw) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY: 711)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate: Start of treatment: Start date Continuation of therapy, Date of				,
Precertification Requested By:		Phone:	Fax:	
A. PATIENT INFORMATION				
First Name:	Last Name:		DOB:	
Address:		City:	State:	ZIP:
Home Phone: Work Phone:		Cell Phone:	Email:	
Patient Current Weight: lbs or kgs Patien	t Heiaht: inches	or cms Allergie	 es:	
B. INSURANCE INFORMATION	<u> </u>			
Aetna Member ID #:	Does patient have other coverage?			
Group #:	If yes, provide ID#: Carrier Name:			
Insured:	Insured:			
Medicare: ☐ Yes ☐ No If yes, provide ID #:	Me	edicaid: Yes No	If yes, provide ID #:	
C. PRESCRIBER INFORMATION				
First Name:	Last Name:		-	☐ D.O. ☐ N.P. ☐ P.A.
Address:		City:	State:	ZIP:
Phone: Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:	Office Contact Name	:	Phone:	
Specialty (Check one): $\square$ Ophthalmologist $\square$ Other	:			
D. DISPENSING PROVIDER/ADMINISTRATION INFOR	RMATION			
Place of Administration:  Self-administered Physician's Office Outpatient Infusion Center Phone: Center Name: Home Infusion Center Phone: Agency Name: Administration code(s) (CPT):		Dispensing Provider/Pharmacy: Patient Selected choice  Physician's Office Retail Pharmacy  Specialty Pharmacy Other  Name:  Address:  Phone:  Fax:  PIN:  PIN:		
Address:		_   IIN:	PIN:	
E. PRODUCT INFORMATION		F		
Request is for: Tepezza (teprotumumab-trbw) Dose:  F. DIAGNOSIS INFORMATION - Please indicate primary	v ICD code and ansaif	Frequency:		_
		de:		
G. CLINICAL INFORMATION - Required clinical informa				
event (anaphylaxis, anaph an infusion?  Yes No Does the patient have sev outpatient hospital setting  Yes No Does the patient have sig infusion therapy AND the  Please provide a descrip  Yes No Is the patient medically ur	oital setting?  ed an adverse event wit roids, diphenhydramine, hylactoid reactions, myon vere venous access issue?  nificant behavioral issue patient does not have action of the behavioral issues to the patient does not have action of the dehavioral issues the propriate medical persection of the condition:	fluids, other pre-medication cardial infarction, thromboe es that require the use of second and a caregiver?  sue or impairment:  de respiratory, cardiovasculators the patient to a severe connel and equipment?	ns or slowing of infusion in mbolism, or seizures) during pecial interventions only ave impairment that would ar, or renal conditions that adverse event that cann	rate) or a severe adverse ring or immediately after available in the limpact the safety of the at may limit the patient's ot be managed in an

Continued on next page



## Tepezza™ (teprotumumab-trbw) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification

Phone: <u>1-866-752-7021 (TTY: 711)</u>

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB			
G. CLINICAL INFORMATION – (continued) Required clinical information must be completed in its entirety for all precertification requests.						
☐ Yes ☐ No Has the patient been of	diagnosed with thyroid eye disease (TED)	)?				
Yes No Is the requested drug being prescribed by or in consultation with an ophthalmologist?						
☐ Yes ☐ No Does the patient have moderate-to-severe disease?						
☐ Yes ☐ No Does the patient have active or inactive disease?						
Which of the following applies to the	patient?					
☐ Lid retraction ≥2 mm						
☐ Moderate or severe soft-tissue invo	Ivement					
☐ Exophthalmos ≥3 mm above norma	ıl for race and gender					
☐ Inconstant or constant diplopia						
☐ None of the above						
	ed a one-time treatment course consisting every 3 weeks for 7 additional infusions)?	g of 8 infusions given once every 3 weeks	(e.g., 10mg/kg on first infusion,			
H. ACKNOWLEDGEMENT						
Request Completed By (Signature	Required):		Date: /			
any insurance company by providing		a medical procedure or service with the als material information for the purpose vil penalties.				

The plan may request additional information or clarification, if needed, to evaluate requests.